INCYTE

Incyte Corporation is a prominent biopharmaceutical company founded in 2002, specializing in the discovery, development, and commercialization of proprietary therapeutics. The firm maintains a robust portfolio focused on oncology and medical innovation, with flagship products including JAKAFI, a critical treatment for myelofibrosis and polycythemia vera, and Iclusig, a kinase inhibitor utilized for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. By leveraging advanced genomic information and small-molecule drug development, Incyte addresses significant unmet medical needs within the global healthcare sector.

Operating with a workforce of 1,000-5,000 employees, Incyte maintains a significant operational footprint across 15 global locations. The company’s strategic infrastructure supports its mission to deliver novel medicines to patients worldwide. Learn about Incyte's global headquarters for detailed information regarding their primary facility in Wilmington, Delaware, and their broader geographic presence. This operational scale enables the company to manage complex clinical trials, regulatory compliance, and the distribution of its specialized therapeutic pipeline effectively across North America and international markets.

Incyte competes within a highly dynamic pharmaceutical landscape, facing competition from industry leaders such as Vertex, Illumina, and Jazz Pharmaceuticals. The company’s commitment to research and development is reflected in its extensive intellectual property portfolio and ongoing clinical advancements. Meet Incyte's team to gain insights into the leadership and organizational structure driving these scientific breakthroughs. Through continuous investment in biotechnology and strategic partnerships, Incyte remains focused on advancing patient care and maintaining its competitive position in the biopharmaceutical industry.